Eris Lifesciences Ltd (IN:ERIS)
:ERIS
Want to see IN:ERIS full AI Analyst Report?
Total Valuation
Eris Lifesciences Ltd has a market cap or net worth of ₹194.40B. The enterprise value is ₹216.77B.
Market Cap₹194.40B
Enterprise Value₹216.77B
Share Statistics
Eris Lifesciences Ltd has 138,567,260 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding138,567,260
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Eris Lifesciences Ltd’s return on equity (ROE) is 0.16 and return on invested capital (ROIC) is 12.62%.
Return on Equity (ROE)0.16
Return on Assets (ROA)0.08
Return on Invested Capital (ROIC)12.62%
Return on Capital Employed (ROCE)0.16
Revenue Per Employee8.64M
Profits Per Employee1.76M
Employee Count3,620
Asset Turnover0.42
Inventory Turnover3.74
Valuation Ratios
The current PE Ratio of Eris Lifesciences Ltd is 31.0. Eris Lifesciences Ltd’s PEG ratio is 0.38.
PE Ratio31.0
PS Ratio5.67
PB Ratio4.54
Price to Fair Value4.54
Price to FCF354.08
Price to Operating Cash Flow80.32
PEG Ratio0.38
Income Statement
In the last 12 months, Eris Lifesciences Ltd had revenue of 31.29B and earned 6.20B in profits. Earnings per share was 45.33.
Revenue31.29B
Gross Profit14.98B
Operating Income8.41B
Pretax Income6.39B
Net Income6.20B
EBITDA11.11B
Earnings Per Share (EPS)45.33
Cash Flow
In the last 12 months, operating cash flow was 2.39B and capital expenditures -1.17B, giving a free cash flow of 1.22B billion.
Operating Cash Flow2.39B
Free Cash Flow1.22B
Free Cash Flow per Share8.82
Dividends & Yields
Eris Lifesciences Ltd pays an annual dividend of ₹7.21, resulting in a dividend yield of 0.47%
Dividend Per Share₹7.21
Dividend Yield0.47%
Payout Ratio24.10%
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.60
52-Week Price Change-24.01%
50-Day Moving Average1.36K
200-Day Moving Average1.49K
Relative Strength Index (RSI)56.27
Average Volume (3m)2.07K
Important Dates
Eris Lifesciences Ltd upcoming earnings date is Jul 31, 2026, TBA (Confirmed).
Last Earnings DateMay 20, 2026
Next Earnings DateJul 31, 2026
Ex-Dividend Date―
Financial Position
Eris Lifesciences Ltd as a current ratio of 0.74, with Debt / Equity ratio of 60.44%
Current Ratio0.74
Quick Ratio0.53
Debt to Market Cap0.13
Net Debt to EBITDA2.06
Interest Coverage Ratio4.36
Taxes
In the past 12 months, Eris Lifesciences Ltd has paid -89.70M in taxes.
Income Tax-89.70M
Effective Tax Rate-0.01
Enterprise Valuation
Eris Lifesciences Ltd EV to EBITDA ratio is 18.02, with an EV/FCF ratio of 399.84.
EV to Sales6.40
EV to EBITDA18.02
EV to Free Cash Flow399.84
EV to Operating Cash Flow57.71
Balance Sheet
Eris Lifesciences Ltd has ₹839.20M in cash and marketable securities with ₹23.89B in debt, giving a net cash position of -₹23.05B billion.
Cash & Marketable Securities₹839.20M
Total Debt₹23.89B
Net Cash-₹23.05B
Net Cash Per Share-₹166.34
Tangible Book Value Per Share-₹42.70
Margins
Gross margin is 47.85%, with operating margin of 26.86%, and net profit margin of 19.80%.
Gross Margin47.85%
Operating Margin26.86%
Pretax Margin20.40%
Net Profit Margin19.80%
EBITDA Margin35.49%
EBIT Margin26.56%
Analyst Forecast
The average price target for Eris Lifesciences Ltd is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast8.15%
EPS Growth Forecast75.47%